Business
Secures new revolving credit facility
Secures new revolving credit facility.
About this update from Allergy Therapeutics Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 4784A\n Allergy Therapeutics PLC\n 02 February 2022\n \n \n \n \n \n \n \n Allergy Therapeutics plc\n \n \n (\"Allergy Therapeutics\", \"ATL\" or the \"Group\")\n \n \n \n \n \n \n \n \n Allergy Therapeutics secures new revolving credit facility\n \n \n \n \n \n \n 2 February 2022 \n \n Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today announces the signing of a new £10m revolving credit facility.\n \n \n \n \n \n The Group has agreed the facility with Natwest, replacing its previous £7m overdraft facility. The facility is for a three year period with the ability to extend annually for a further two years. This new facility is intended to provide additional security to the Group's current credit facilities. \n \n \n \n \n \n Allergy Therapeutics also has various loans held in its Spanish subsidiary, which amounted to £2.9m as at 31 December 2021. These remain in place. \n \n \n \n \n \n \n \n \n This announcement contains inside information for the purposes of Article 7 of Regulatory (EU) No596/2014.\n \n \n \n \n \n - ENDS -\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n For further information, please contact:\n \n \n \n \n \n Allergy Therapeutics\n \n \n +44 (0) 1903 845 820\n \n \n Manuel Llobet, Chief Executive Officer\n \n \n Nick Wykeman, Chief Financial Officer\n \n \n \n \n \n Panmure Gordon\n \n \n +44 (0) 20 7886 2500\n \n \n Freddy Crossley, Emma Earl, Corporate Finance\n \n \n Rupert Dearden, Corporate Broking\n \n \n \n \n \n Consilium Strategic Communications\n \n \n +44 20 3709 5700\n \n \n Mary-Jane Elliott / David Daley / Davide Salvi\n \n \n \n [email protected]\n \n \n \n \n \n \n Stern Investor Relations, Inc.\n \n \n +1 212 362 1200\n \n \n Christina Tartaglia\n \n \n \n [email protected]\n \n \n \n \n \n \n \n \n \n Notes for editors:\n \n \n \n \n \n About Allergy Therapeutics\n \n \n \n \n \n Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and th...